Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

Dispatch Bio, a company aiming to engineer a universal immunotherapy treatment across solid tumors, announced its official launch.

July 25, 2025

Vol.51 No.29

In Brief

Geraldine O’Sullivan Coyne to lead early-stage clinical trials at Northwell’s START Center for Cancer Research

Geraldine O’Sullivan Coyne was appointed system head of Northwell and principal investigator for the START Center for Cancer Research, a newly established unit at the health system aimed at bringing innovative early stage clinical trials to patients in a community-based cancer center.

July 25, 2025

Vol.51 No.29

Drugs & Targets

EC approves Cabometyx for advanced neuroendocrine tumors

The European Commission has approved Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic and extra-pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

July 25, 2025

Vol.51 No.29

Podcast

In the Headlines: Is oncology ready to move away from animal testing?

NIH has announced it will stop issuing funding opportunities solely dedicated to animal models, but has not published any formal guidance related to the announcement, and researchers are unclear on when or whether further policy materials are to be expected.

July 23, 2025

Vol.51 No.28